Silo Pharma, Inc.
SILO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0% | 0% | 1.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 91.9% | 91.9% | 91.9% | 93% |
| R&D Expenses | $2 | $1 | $1 | $1 |
| G&A Expenses | $2 | $3 | $2 | $2 |
| SG&A Expenses | $2 | $3 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | -$0 |
| Operating Expenses | $5 | $4 | $4 | $3 |
| Operating Income | -$5 | -$4 | -$4 | -$3 |
| % Margin | -6,526.4% | -5,347.4% | -5,031.3% | -3,851% |
| Other Income/Exp. Net | $0 | $0 | -$0 | $7 |
| Pre-Tax Income | -$4 | -$4 | -$4 | $4 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$4 | -$4 | $4 |
| % Margin | -6,092.6% | -5,132.6% | -5,420.9% | 5,477.9% |
| EPS | -1.19 | -1.2 | -1.71 | 1.32 |
| % Growth | 0.8% | 29.8% | -229.5% | – |
| EPS Diluted | -1.19 | -1.2 | -1.71 | 1.3 |
| Weighted Avg Shares Out | 4 | 3 | 2 | 2 |
| Weighted Avg Shares Out Dil | 4 | 3 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$4 | -$4 | $4 |
| % Margin | -6,077% | -5,029.3% | -5,416.2% | 5,872.6% |